CTI BioPharma Corp (fka CTIC)

[barnyarddog]

Jun 01, 2020, CTI BioPharma Announces Enrollment of First Patient in COVID-19 PRE-VENT Phase 3 Clinical Trial
- Company Expects to Report Topline Data by the End of 2020 - SEATTLE , June 1, 2020 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today announced that it has enrolled the first patient in the Phase 3 PRE-VENT trial (NCT04404361) of pacritinib in hospitalized patients with severe COVID-19.

https://cbc.gcs-web.com/news


About Us

We are a Seattle based biopharmaceutical company focused on the development and commercialization of novel therapies that address unique unmet medical needs for patients suffering from blood-related cancers. Pacritinib, our lead product candidate is in development for the treatment of myelofibrosis which has the potential to fulfill a significant treatment gap in the management of these patients due to it’s unique clinical profile.